Breaking News Instant updates and real-time market news.

CDNA

CareDx

$3.25

-0.1 (-2.99%)

15:04
11/18/16
11/18
15:04
11/18/16
15:04

CareDx: AlloSure detects active rejection in kidney transplant patients

CareDx has presented compelling AlloSure data at the American Society of Nephrology Annual Meeting. AlloSure is a clinical-grade proprietary Next-Generation Sequencing based test to detect donor-derived cell-free DNA, dd-cfDNA, in solid organ transplant recipients. The DART clinical trial is a landmark study for CareDx with 14 transplant centers across the United States. The study started in 2015 and this first analysis is from a dataset with 1272 samples from 384 patients. Key takeaways from the data: AlloSure differentiates "Active Rejection" from "Non Rejection"; Assay has sensitivity of 59% and specificity of 85% at a 1% threshold; AlloSure provides PPV of 60% at a 1% threshold and 85% at a 3% threshold; AlloSure provides NPV of 84% at a 1% threshold and 80% at a 3% threshold

  • 29

    Nov

CDNA CareDx
$3.25

-0.1 (-2.99%)

06/13/16
LEER
06/13/16
NO CHANGE
LEER
CMS price proposals for diagnostic tests a negative for most, says Leerink
Leerink analyst Dan Leonard expects several diagnostics stocks to underperform following proposed price cuts or low initial reimbursement rates by the Centers for Medicare and Medicaid Services, or CMS, for diagnostic tests. If finalized, the preliminary pricing would negatively impact CareDx (CDNA), Veracyte (VCYT), and InVitae (NVTA), the analyst tells investors in a research note, adding that he also sees an indirect negative read-through for Illumina (ILMN).
06/13/16
CANT
06/13/16
NO CHANGE
Target $13
CANT
Buy
Cantor sees 'flawed methodology' with new CMS rates
Cantor Fitzgerald analyst Bryan Brokmeier says shares of Veracyte (VCYT) may be under pressure this morning following Friday's release of a proposed gapfill Medicare reimbursement rate reduction on the company's Afirma GEC. Along with the 30% reduction on Afirma's GEC, the release from the Centers for Medicare and Medicaid Services resets rates on 15 other molecular diagnostic tests, including reductions in CareDx's (CNDA) AlloMap, which is down 74%, Genomic Health's (GHDX) Oncotype Dx Colon, which is down 73%, and Rosetta Genomics' (ROSG) Cancer Origin Test, which is down 57%, Brokmeier tells investors in a research note. The analyst, however, believes the preliminary proposed gapfill rate is based on a "flawed methodology" because it is the median proposed rate submitted by all Medicare Administrative Contractors, including those that have little or no experience administering claims on these tests, Brokmeier contends. He points out that Medicare represents approximately 20% of Afirma GEC test volume for Veracyte. Based on 2015 volume, the 30% Medicare rate reduction for Afirma would reduce total revenues by $3.7M or 7.5%, he adds. The analyst keeps a Buy rating on Veracyte with a $13 price target.
06/20/16
PIPR
06/20/16
NO CHANGE
PIPR
Final PAMA rule better than expected, says Piper Jaffray
Piper Jaffray analyst William Quirk says the final Protecting Access to Medicare Act published Friday by Centers for Medicare & Medicaid Services is better than expected. PAMA is delayed until 2018 from 2017 as expected, Quirk tells investors in a research note. Hospital labs will be required to submit private payer rates to CMS, a positive relative to prior expectations, the analyst notes. He views the decision as beneficial for Quest Diagnostics (DGX) and LabCorp (LH). Further, CMS will require labs to submit only in-network rates and out-of-network "final" rates, which is a positive for specialty labs who have in-network rates at or above Medicare including CareDx (CDNA), Genomic Health (GHDX), Myriad Genetics (MYGN), Oxford Immunotec (OXFD) and Veracyte (VCYT), Quirk writes.
07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).

TODAY'S FREE FLY STORIES

TOL

Toll Brothers

$30.09

0.77 (2.63%)

13:38
12/05/16
12/05
13:38
12/05/16
13:38
Technical Analysis
Toll Brothers technical comments before earnings, potential bullish pattern »

There is a potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

13:35
12/05/16
12/05
13:35
12/05/16
13:35
General news
NY Fed's overnight reverse repo totaled $168.4 B, with 51 counterparties »

NY Fed's overnight…

FTI

FMC Technologies

$36.35

0.75 (2.11%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

13:31
12/05/16
12/05
13:31
12/05/16
13:31
Hot Stocks
FMC Technologies, Technip shareholders approve business combination »

FMC Technologies (FTI)…

FTI

FMC Technologies

$36.35

0.75 (2.11%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

NVS

Novartis

$69.06

0.89 (1.31%)

13:26
12/05/16
12/05
13:26
12/05/16
13:26
Hot Stocks
Novartis' MPN survey results 'help quantify' daily difficulty of MPN »

Novartis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AXP

American Express

$72.24

0.38 (0.53%)

13:25
12/05/16
12/05
13:25
12/05/16
13:25
Hot Stocks
Barclays turns focus on American Express toward enterprise strength »

Research firm Barclays…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CBS

CBS

$61.26

1.075 (1.79%)

, T

AT&T

$38.81

0.2 (0.52%)

13:22
12/05/16
12/05
13:22
12/05/16
13:22
Hot Stocks
CBS CEO: AT&T will not get Showtime for $5 a month »

CBS (CBS) CEO Moonves…

CBS

CBS

$61.26

1.075 (1.79%)

T

AT&T

$38.81

0.2 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

FRBK

Republic First Bancorp

$5.35

-0.05 (-0.93%)

13:22
12/05/16
12/05
13:22
12/05/16
13:22
Hot Stocks
Republic First Bancorp elects Vernon Hill as chairman »

Republic First Bancorp,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$61.25

1.07 (1.78%)

, T

AT&T

$38.79

0.18 (0.47%)

13:20
12/05/16
12/05
13:20
12/05/16
13:20
Hot Stocks
CBS CEO says will make deal with DirecTV online »

CBS (CBS) CEO Leslie…

CBS

CBS

$61.25

1.07 (1.78%)

T

AT&T

$38.79

0.18 (0.47%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 15

    Jan

YUM

Yum! Brands

$63.07

0.65 (1.04%)

13:20
12/05/16
12/05
13:20
12/05/16
13:20
Options
3X average daily option volume in Yum Brands as players gobble up Jan 65 calls »

3X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CBS

CBS

$61.24

1.055 (1.75%)

, T

AT&T

$38.80

0.185 (0.48%)

13:19
12/05/16
12/05
13:19
12/05/16
13:19
Hot Stocks
CBS CEO says in discussions over DirecTV NOW »

Says industry needs total…

CBS

CBS

$61.24

1.055 (1.75%)

T

AT&T

$38.80

0.185 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

$NYE

NYSE Market Internals

13:16
12/05/16
12/05
13:16
12/05/16
13:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:16
12/05/16
12/05
13:16
12/05/16
13:16
Technical Analysis
NASDAQ market internals summary »

Volume is extremely heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

, SNY

Sanofi

$40.79

0.77 (1.92%)

13:15
12/05/16
12/05
13:15
12/05/16
13:15
Hot Stocks
Alnylam 'pleased' with updated ALN-CC5 Phase 1/2 trial results »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

SNY

Sanofi

$40.79

0.77 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

DPZ

Domino's Pizza

$168.06

0.06 (0.04%)

13:14
12/05/16
12/05
13:14
12/05/16
13:14
Hot Stocks
Domino's locations throughout Phoenix to hire 300 new team members »

Domino's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

CYNO

Cynosure

$44.35

-0.7 (-1.55%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Conference/Events
Cynosure management to meet with Maxim »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Hot Stocks
Global Blood Therapeutics announces details on PRO tool in phase 3 HOPE study »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CBS

CBS

$61.09

0.905 (1.50%)

, NFLX

Netflix

$120.81

3.59 (3.06%)

13:11
12/05/16
12/05
13:11
12/05/16
13:11
Hot Stocks
CBS' Moonves: 2017 will be 'very strong year' for company »

CBS (CBS) CEO Moonves…

CBS

CBS

$61.09

0.905 (1.50%)

NFLX

Netflix

$120.81

3.59 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 12

    Dec

CSIQ

Canadian Solar

$11.07

-0.21 (-1.86%)

13:10
12/05/16
12/05
13:10
12/05/16
13:10
Options
Calls active in Canadian Solar as shares see relative strength »

Calls active in Canadian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

COST

Costco

$152.09

0.35 (0.23%)

13:08
12/05/16
12/05
13:08
12/05/16
13:08
Periodicals
Ontario regulator investigating Costco allegations, STAT reports »

Ontario's Ministry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

13:07
12/05/16
12/05
13:07
12/05/16
13:07
Hot Stocks
Seattle Gen.: Patients in ADCETRIS trial achieve significant durable remissions »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SMCI

Super Micro Computer

$27.00

0.8 (3.05%)

13:07
12/05/16
12/05
13:07
12/05/16
13:07
Conference/Events
Super Micro Computer management to meet with Maxim »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Feb

  • 09

    Feb

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

13:04
12/05/16
12/05
13:04
12/05/16
13:04
Hot Stocks
Juno announces 'encouraging' preliminary JCAR017 clinical data for NHL patients »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

13:04
12/05/16
12/05
13:04
12/05/16
13:04
Hot Stocks
Bellicum Pharmaceuticals announces GoCAR-T, GoTCR presentations at meeting »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CBS

CBS

$61.03

0.85 (1.41%)

, VIA

Viacom

$40.35

-1 (-2.42%)

13:02
12/05/16
12/05
13:02
12/05/16
13:02
Hot Stocks
CBS CEO: Company 'very happy' as standalone group »

CBS (CBS) chairman and…

CBS

CBS

$61.03

0.85 (1.41%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 12

    Dec

UAL

United Continental

$68.28

-0.99 (-1.43%)

13:02
12/05/16
12/05
13:02
12/05/16
13:02
Hot Stocks
United Continental technicians ratify joint collective bargaining agreement »

United Airlines announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.